Interleukin-1 receptor 1 deficiency worsens hepatocellular carcinoma, while gemcitabine treatment alleviates the hepatocellular carcinoma-induced increase in intra-hepatic immune cells.
Chia-Sheng ChuHsiao-Ping ChenPin-Hung LinChi-Chen ChengHo-Yu KuoPei-Han FanWei-Hao PengLi-Ling WuPublished in: Journal of gastroenterology and hepatology (2024)
Targeting IL-1 or combining gemcitabine with immunotherapy is a promising approach for treating advanced-stage HCC.